Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients

Authors

Chelsea Payne, University of Rochester Medical Center
Jennifer I. Melaragno, University of Rochester Medical Center
David Hutchinson, St. John Fisher UniversityFollow
Tara M. Babu, University of Rochester Medical Center
Paritosh Prasad, University of Rochester Medical Center
Travis B. Dick, University of Rochester Medical Center

Document Type

Poster Presentation

Publication Date

4-30-2017

Abstract

Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can cause hematologic toxicities. Prior studies in OLT have demonstrated comparable efficacy of low dose (LD)-VGCV to oral ganciclovir, but the efficacy of LD-VGCV compared to standard dose (SD) VGCV has not been established. Herein we describe the first report comparing LD-VGCV to SD-VGCV for the prevention of CMV in OLT.

DOI

https://doi.org/10.1111/ajt.14306

Comments

Poster presented at the 2017 American Transplant Congress (ATC) in Chicago, Illinois, April 30 2017.

Abstract published in the American Journal of Transplantation Volume 17, Issue S3 Special Issue: 2017 American Transplant Congress Abstracts: https://doi.org/10.1111/ajt.14306

Abstract also available on the conference website.

Publication Information

Payne, Chelsea; Melaragno, Jennifer I.; Hutchinson, David; Babu, Tara M.; Prasad, Paritosh; and Dick, Travis B. (2017). "Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients." American Journal of Transplantation 17.S3, 577-578.

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.